How to Manage Post-Market Surveillance for Medical Devices in China
China’s medical device post-market surveillance (PMS) system processed over 650,000 adverse event reports in 2024, reflecting a regulatory environment that is rapidly maturing — and becoming more demanding for foreign manufacturers. The National Medical Products Administration (NMPA) has progressively tightened post-market requirements since 2019, introducing mandatory adverse event monitoring systems, periodic risk assessments, and field inspections that now affect all Class II and III device registrants. For foreign manufacturers already marketing devices in China, compliance with PMS obligations is no longer a back-office function — it is a core regulatory requirement with direct consequences for product registration renewal, market access, and liability exposure.
Understanding the Regulatory Framework for Post-Market Surveillance in China
The legal foundation for medical device PMS in China is established by the Regulations on the Supervision and Administration of Medical Devices (State Council Decree No. 739, 2021) and its implementing rules. The NMPA requires all registrants to maintain a comprehensive PMS system covering adverse event monitoring, product safety updates, corrective action implementation, and periodic reporting. The regulatory framework draws heavily from the Global Harmonization Task Force (GHTF) model but incorporates China-specific requirements that foreign manufacturers must carefully navigate.
Key regulatory documents include the Measures for the Administration of Medical Device Adverse Event Monitoring and Re-evaluation (2023 revision), which expanded the scope of reportable events to include not only serious adverse events but also near-miss incidents and product quality defects that could potentially lead to adverse outcomes. The revised measures also introduced tiered reporting timelines: serious adverse events must be reported within 7 days, events requiring intervention within 20 days, and all other reportable incidents within 30 days.
| Regulatory Instrument | Primary Requirements | Applicable Devices |
|---|---|---|
| Adverse Event Monitoring | Real-time reporting via ADR monitoring system; tiered severity timelines | Class II & III |
| Periodic Risk Assessment Report | Annual submission with risk-benefit analysis, corrective actions | All registered devices |
| Field Safety Corrective Action (FSCA) | Mandatory notification to NMPA within 72 hours; public safety notice | Class II & III |
| Product Quality Re-evaluation | NMPA-initiated review triggered by safety signals or incidents | Any device class |
| Registration Renewal Dossier | Updated PMS data required every 5 years for renewal | All registered devices |
Foreign manufacturers must establish a China-based PMS entity — either a local subsidiary, a liaison office, or a designated agent — that serves as the point of contact for NMPA communications and bears direct regulatory responsibility for PMS compliance. This entity must have qualified personnel who understand both the regulatory requirements and the Chinese language requirements for documentation.
Setting Up an Adverse Event Monitoring System Compliant with NMPA Requirements
The NMPA requires all registrants of Class II and III medical devices to maintain a real-time adverse event (AE) monitoring system integrated with the national Medical Device Adverse Event Monitoring Information System, a centralized platform operated by the Center for Medical Device Adverse Event Monitoring under the NMPA. The system must be capable of receiving, processing, and reporting AEs within the statutory timelines — 7 calendar days for serious AEs, 20 days for events requiring medical intervention, and 30 days for other reportable events.
Foreign manufacturers should implement an AE monitoring process that covers the complete product lifecycle, from initial patient contact through post-procedure follow-up. The monitoring system must include mechanisms for detecting, documenting, and assessing AEs from multiple sources: spontaneous reports from healthcare professionals and patients, literature surveillance for published case reports, post-market clinical follow-up studies, customer complaint data from distributors, and quality control data from manufacturing batches destined for China.
The monitoring system must be documented in a standard operating procedure (SOP) written in Chinese, approved by the local regulatory representative, and available for NMPA inspection. The SOP should define clear roles and responsibilities, escalation procedures, severity classification criteria aligned with NMPA definitions, and a corrective action protocol. An annual system audit by a qualified third party is strongly recommended.
- Designate a China-based PMS officer with regulatory expertise and Chinese language proficiency
- Establish a digital AE intake system that interfaces with the NMPA monitoring platform
- Implement a 7-day serious AE escalation protocol with 24/7 reporting capability
- Develop Chinese-language SMAF forms and reporting templates compliant with NMPA formats
- Conduct annual simulated AE drills to validate system responsiveness and staff training
Preparing and Submitting Periodic Risk Assessment Reports
The Periodic Risk Assessment Report (PRAR) is a comprehensive document that registrants must submit to the NMPA annually for all registered medical devices. The PRAR summarizes the device’s safety profile over the reporting period, including adverse event data, risk-benefit analysis, corrective actions taken, and any changes to the device design or manufacturing that could affect safety or performance. The NMPA uses the PRAR as a primary input for determining whether to renew a device’s registration certificate, which is valid for five years.
The PRAR must include a quantitative analysis of adverse event rates compared to the previous reporting period, with statistical significance testing for any observed increases. For devices with cumulative AEs, the report must present a time-trend analysis identifying any emerging safety signals. The PRAR must also include a literature review of published safety data from Chinese and international journals, a summary of FSCAs issued during the period, and a corrective action plan with measurable timelines for implementation. Foreign manufacturers must translate all supporting documentation into Chinese and have the report reviewed and certified by the local regulatory representative before submission.
Managing Field Safety Corrective Actions (FSCAs) in China
When a medical device safety issue is identified through the AE monitoring system or other sources, the registrant must initiate a Field Safety Corrective Action (FSCA). FSCAs include product recalls, safety alerts, field modifications, software updates, and changes to labeling or instructions for use. The NMPA requires that FSCAs be reported within 72 hours of the registrant’s decision to take corrective action. The notification must include the device identification details, a description of the safety issue and its root cause, the affected batch or lot numbers, and the proposed corrective action plan.
The FSCA process in China has several distinctive features. The NMPA requires that all FSCAs be publicly announced through a government-designated channel — typically the provincial Medical Product Administration website — to ensure widespread dissemination to healthcare facilities and patients. For Class III and implantable devices, the manufacturer must also implement a patient notification system, which may include direct contact through healthcare providers or public service announcements. The NMPA has the authority to independently audit the FSCA implementation at the registrant’s facilities and can order expanded corrective actions if the proposed plan is deemed insufficient.
Preparing for NMPA On-Site Inspections of PMS Systems
The NMPA conducts on-site inspections of medical device registrants’ PMS systems as part of its routine regulatory oversight program. Approximately 15% of Class II and III device registrants are inspected annually, with higher rates for manufacturers of high-risk devices (cardiovascular implants, orthopedic devices, active implantable devices). The inspection teams typically consist of 2–4 inspectors from the NMPA or provincial Medical Product Administration and review the registrant’s PMS documentation for compliance with the applicable regulations and standards.
During a PMS inspection, NMPA inspectors evaluate the following areas: the completeness and accuracy of AE records, including timeliness of reporting; the quality and completeness of PRAR submissions; evidence of corrective action implementation and effectiveness; staff training records for PMS procedures; the adequacy of the local PMS entity’s resources and qualifications; and data integrity of the AE monitoring system. Inspectors may request access to the registrant’s electronic AE database, interview PMS staff, and cross-reference AE reports with distributor and hospital records. Foreign manufacturers should maintain all PMS records in both the original language and Chinese translation, with the Chinese version clearly marked as the regulatory-referenced copy.
Integrating PMS with Registration Renewal and Market Access Strategy
Post-market surveillance data has a direct and increasingly important impact on device registration renewal. The NMPA’s registration certificate renewal process now requires a comprehensive PMS dossier as a mandatory component of the application. Devices with an adverse event rate significantly higher than the industry benchmark may face renewal delays, additional data requirements, or — in extreme cases — certificate non-renewal. The NMPA publishes quarterly adverse event statistics benchmarked by device category, allowing manufacturers to track their performance relative to peers.
Foreign manufacturers should consider PMS not merely as a compliance obligation but as a strategic asset for maintaining and expanding their Chinese market access. A robust PMS system generates real-world evidence that can support labeling expansions, regulatory approvals for new indications, and competitive differentiation in hospital procurement processes. Manufacturers with well-documented PMS systems and favorable safety profiles may qualify for expedited NMPA review pathways for new device versions, reducing time-to-market by 6–12 months.
- Proactive PMS strategy: Invest in China-specific clinical data collection to support labeling claims and demonstrate local safety performance.
- Early warning integration: Connect your global AE database with the China AE monitoring system to ensure consistent signal detection.
- Distributor coordination: Train your China distributors on AE reporting obligations — they are often the first point of contact for hospital complaints.
- Regulatory intelligence: Subscribe to NMPA ADR monitoring newsletters and participate in industry working groups to anticipate regulatory changes.
Where to Go From Here
An effective post-market surveillance system is a regulatory necessity and a competitive advantage for foreign medical device manufacturers in China. Building the right infrastructure, processes, and relationships with NMPA takes time — but the commercial stakes in the Chinese market make this investment essential.
- Ready to act? Read a step-by-step guide to implementing an NMPA-compliant PMS system
- Still comparing? See a side-by-side comparison of PMS requirements in China, EU, and US
- Need numbers? Try an interactive PMS cost calculator for medical device registrants in China
How to Manage Post-Market Surveillance for Medical Devices in China — first published on China Gateway 360. Last updated: July 2026.
Management and Implementation Framework
Work on post-market surveillance for medical devices in china should begin with a documented business objective, not a form or provider quotation. The team should identify the China activity, responsible entity, location, expected start date, transaction or employee population and internal risk tolerance. These facts determine which approvals, records and controls are proportionate.
Sequence the implementation
A practical sequence moves from fact confirmation to option selection, document preparation, authority or counterparty review, implementation and post-launch verification. Dependencies should be visible. No team should assume that registration, a signed contract or a successful system submission proves operational readiness; bank, tax, HR, finance and local operating steps often have separate completion evidence.
Control ownership and evidence
Management control depends on assigning decisions before deadlines become urgent. For post-market surveillance for medical devices in china, the accountable group normally includes the regulatory affairs lead, quality owner, China agent and responsible product executive. Responsibility should be divided between preparation, approval and independent checking. The core file should contain classification evidence, technical dossier, clinical or performance data, quality-system documents, registration correspondence and vigilance records. Evidence should be dated, attributable to a named owner and linked to the decision or filing it supports. Verbal confirmation is not a substitute for a retained authority notice, counterparty response or approved internal record.
The control calendar should reflect the classification, dossier preparation, authority review, market release and post-market surveillance. Dependencies and cut-off dates need to be visible to every function that supplies data. Any external provider should receive a written scope, required inputs, response timetable and escalation route. The company remains responsible for reviewing outputs even when execution is outsourced. Known failure modes include incorrect classification, unsupported claims, dossier inconsistency, agent-control gaps and weak adverse-event handling; each should have a preventive check and a named reviewer.
Management review and escalation
The review meeting should focus on exceptions and unresolved assumptions. The status pack should show the decision required, facts confirmed, assumptions still open, monetary or operational exposure, next deadline and responsible owner. Items that depend on local discretion should be labelled clearly. Escalation should occur when an authority rejects a filing, a counterparty requests materially different evidence, a cost or timing threshold is exceeded, or actual operations no longer match the approved setup.
Before go-live, the responsible executive should confirm that legal form, contracts, system configuration, payment authority and record retention are aligned. A short post-implementation review after the first operating cycle should compare planned and actual time, cost and exceptions. That review is where recurring controls are corrected and where lessons become part of the company standard rather than remaining with an individual adviser.
Practical completion checklist
- State the business decision, scope, city, entity and target date.
- Confirm the current official rule and any local implementation requirement.
- Assign preparation, approval and independent review to named owners.
- Retain the documents, calculations and correspondence supporting the decision.
- Test cost, timing and operational assumptions against a downside case.
- Record unresolved issues and the threshold for management escalation.
- Verify the first completed operating cycle and update the control calendar.
Execution Record and Handover
The final record for post-market surveillance for medical devices in china should allow another manager to understand what was decided, which evidence was relied on and which obligations remain open. The handover pack should identify the current operating assumption, the approving executive, the external authority or counterparty involved, the effective date and the next mandatory review. It should also explain any local interpretation, exception or temporary workaround so that it is not mistaken for a permanent rule.
For medical, continuity depends on preserving classification evidence, technical dossier, clinical or performance data, quality-system documents, registration correspondence and vigilance records. Files should use a consistent naming convention and access should follow the company’s authority matrix. Critical dates belong in a controlled calendar rather than an individual’s inbox. Where a provider holds original submissions or account credentials, the contract and exit plan should guarantee prompt return of records in a usable format.
A quarterly control check should sample one completed transaction or employee cycle, reconcile it to the approved process and record exceptions. Material deviations should be assigned to an owner with a due date; repeated deviations should trigger a process redesign rather than another informal reminder. This creates a defensible link between policy, daily execution and management oversight while keeping the control proportionate to the actual China operation.
